UroGen Pharma Ltd. (URGN)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 697.98M |
| Enterprise value | 632.16M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 6.31 |
| Price/book (mrq) | N/A |
| Enterprise value/revenue | 7.50 |
| Enterprise value/EBITDA | -2.63 |
Trading information
Stock price history
| Beta (5Y monthly) | 1.09 |
| 52-week change 3 | 65.97% |
| S&P500 52-week change 3 | 22.55% |
| 52-week high 3 | 24.13 |
| 52-week low 3 | 8.69 |
| 50-day moving average 3 | 14.30 |
| 200-day moving average 3 | 14.56 |
Share statistics
| Avg vol (3-month) 3 | 597.22k |
| Avg vol (10-day) 3 | 1.42M |
| Shares outstanding 5 | 41.13M |
| Implied shares outstanding 6 | 41.64M |
| Float 8 | 22.28M |
| % held by insiders 1 | 9.52% |
| % held by institutions 1 | 73.99% |
| Shares short (14 Jun 2024) 4 | 5.62M |
| Short ratio (14 Jun 2024) 4 | 7.3 |
| Short % of float (14 Jun 2024) 4 | 16.13% |
| Short % of shares outstanding (14 Jun 2024) 4 | 15.56% |
| Shares short (prior month 15 May 2024) 4 | 4.47M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | -123.74% |
| Operating margin (ttm) | -137.05% |
Management effectiveness
| Return on assets (ttm) | -27.60% |
| Return on equity (ttm) | N/A |
Income statement
| Revenue (ttm) | 84.3M |
| Revenue per share (ttm) | 2.69 |
| Quarterly revenue growth (yoy) | 9.20% |
| Gross profit (ttm) | N/A |
| EBITDA | -68.52M |
| Net income avi to common (ttm) | -104.32M |
| Diluted EPS (ttm) | -3.22 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 164.04M |
| Total cash per share (mrq) | 4.54 |
| Total debt (mrq) | 99.01M |
| Total debt/equity (mrq) | N/A |
| Current ratio (mrq) | 7.47 |
| Book value per share (mrq) | -1.11 |
Cash flow statement
| Operating cash flow (ttm) | -82.3M |
| Levered free cash flow (ttm) | -40M |
© 2024 Yahoo. All rights reserved.